This article was originally published in The Gray Sheet
Topics for discussion at the eighth annual Health Industry Manufacturers Association device submissions workshop June 27-29 include FDA's allocation of resources for implementation of the FDA Modernization Act, 510(k) and premarket approval application reengineering initiatives, advertising and promotion, labeling and expedited review. Device center staffers scheduled to speak include: Susan Alpert, director of FDA's Office of Device Evaluation, Phil Phillips, ODE deputy director, and Byron Tart, director, promotion and advertising policy staff. The conference is being held at the Omni Shoreham hotel in Washington, D.C. Contact James Blanchard at 202/434-7231 for additional information...
You may also be interested in...
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.